RxDoctor Payments Data

Scott Woolf, MD

Glaucoma Specialist · Boise, IDNPI 1629509682

Payments from drug & device makers

$3,806in general payments, 2019–2025

Across 91 payments — averaging $41.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$937
  • AbbVie$661
  • Glaukos Corporation$528
  • Bausch & Lomb Americas Inc.$456
  • NEW World Medical,inc.$306
  • Harrow Eye, LLC$298
  • plus $621 from 7 others

What the payments were for

  • Speaking & faculty fees$391%
  • Food & beverage$3,74198%
  • Gifts$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$367,962
Medicare patients
697
Services billed
2,804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost46$25,136
Prednisolone Acetate484$12,867
RhopressaNetarsudil Mesylate28$8,768
Ketorolac Tromethamine447$8,539
Latanoprost969$8,325
RocklatanNetarsudil Mesylat/Latanoprost12$6,065
Cyclosporine11$5,917
Alphagan PBrimonidine Tartrate17$5,342
TafluprostTafluprost/Pf36$4,981
Travoprost24$4,742
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol23$4,450
Ofloxacin377$4,243
CombiganBrimonidine Tartrate/Timolol14$3,478
Timolol Maleate365$2,942
Dorzolamide-TimololDorzolamide/Timolol/Pf15$2,166

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$661$33,95677 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Idahoon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Boise

Where these figures come from

Is this you, or does something look wrong? →